Article
Oncology
In Hye Song, Young-Ae Kim, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, Yeon Ho Choi, Heejae Lee, Jeong-Han Seo, Youngjin Cho, Sung Wook Jung, Hee Jeong Kim, Sei Hyun Ahn, Hee Jin Lee, Gyungyub Gong
Summary: The study found that the expression of MHC I and TIL levels may be affected by ER pathway modulation and IFN treatment. Further research elucidating the mechanism of MHC I regulation could suggest a way to boost TIL influx in cancer in a clinical setting.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Sachie Hashimoto, Emiko Noguchi, Hiroko Bando, Hiroko Miyadera, Wataru Morii, Takako Nakamura, Hisato Hara
Summary: The study found that predicting neoantigens using RNA-seq data has high false-positive and false-negative rates, depending greatly on the expression status of normal genes. Compared to using WES data, the combination method is more effective in detecting highly expressed neoantigens.
Article
Oncology
Inho Park, Yangkyu Lee, Jee Hung Kim, Soong June Bae, Sung Gwe Ahn, Joon Jeong, Yoon Jin Cha
Summary: This study reveals a negative correlation between YAP1 expression and Oncotype Dx (ODX) test risk score (RS) in patients with hormone-receptor-positive, HER2-negative (HR+HER2-) breast cancer. Elevated YAP1 mRNA levels are associated with better clinical outcomes. Superior survival outcomes are consistently observed in subsets with different ESR1 mRNA expression and pronounced YAP1 expression.
Article
Biochemistry & Molecular Biology
Kai-Yen Tsai, Deng-Chyang Wu, Wen-Jeng Wu, Jiunn-Wei Wang, Yung-Shun Juan, Ching-Chia Li, Chung-Jung Liu, Hsiang-Ying Lee
Summary: This study investigates the potential relationship between human microbiota and prostatic disease by analyzing stool and urine samples from patients. The results suggest that the microbiota composition in urine samples is different among different patient populations, indicating a potential link between microbiota and prostatic disease.
Review
Oncology
Chandra K. Maharjan, Jiao Mo, Lei Wang, Myung-Chul Kim, Sameul Wang, Nicholas Borcherding, Praveen Vikas, Weizhou Zhang
Summary: The oncogenic role of estrogen receptor (ER) signaling in breast cancer is well-established. Aberrant estrogen signaling enhances mammary epithelial cell proliferation, survival, and angiogenesis, contributing to breast cancer initiation and progression. Estrogen has been found to have both pro- and anti-inflammatory roles, and xenoestrogens can modulate chronic inflammation and breast cancer development. Understanding the complex relationship between estrogens, inflammation, and breast cancer will inform clinical research on prevention and therapy.
Article
Oncology
Tiziana Triulzi, Viola Regondi, Elisabetta Venturelli, Patrizia Gasparini, Cristina Ghirelli, Jessica Groppelli, Martina Di Modica, Francesca Bianchi, Loris De Cecco, Lucia Sfondrini, Elda Tagliabue
Summary: HER2 mRNA expression is associated with the response to anti-HER2 treatment and is independent of estrogen receptor tumor status in HER2-positive breast cancer patients. HER2 mRNA levels can predict the risk and exhibit distinct biological characteristics compared to HER2 protein levels.
Article
Anesthesiology
Huseyin A. Findikli, Murat Erdogan
Summary: This study found that serum GPER-1 levels are closely associated with the prognosis of sepsis patients, with higher GPER-1 levels being linked to better outcomes. GPER-1 and APACHE II scores can independently predict mortality in sepsis patients.
MINERVA ANESTESIOLOGICA
(2021)
Article
Urology & Nephrology
Firas G. Petros, Woonyoung Choi, Yuan Qi, Tyler Moss, Roger Li, Xiaoping Su, Charles C. Guo, Bogdan Czerniak, Colin Dinney, David J. McConkey, Surena F. Matin
Summary: This study compared different types of urothelial carcinoma in the same patient and found that differences in gene expression may be associated with pathological features. Metachronous tumors largely maintained the molecular subtype membership of the initial tumor.
JOURNAL OF UROLOGY
(2021)
Article
Endocrinology & Metabolism
Minjun Kim, Su-jin Kim, Seong Yun Ha, Zhen Xu, Youngjin Han, Hyeon-Gun Jee, Sun Wook Cho, Young Joo Park, Kyu Eun Lee
Summary: The BRAFV600E mutation plays a crucial role in the estrogen responsiveness of thyroid cancer by regulating the expression of estrogen receptors. This finding suggests that BRAFV600E could be used as a biomarker for hormone therapy decisions in thyroid cancer patients based on estrogen signaling.
ENDOCRINOLOGY AND METABOLISM
(2022)
Article
Oncology
John E. Levine, Stephan A. Grupp, Michael A. Pulsipher, Andrew C. Dietz, Susana Rives, G. Douglas Myers, Keith J. August, Michael R. Verneris, Jochen Buechner, Theodore W. Laetsch, Henrique Bittencourt, Andre Baruchel, Michael W. Boyer, Barbara De Moerloose, Muna Qayed, Stella M. Davies, Christine L. Phillips, Timothy A. Driscoll, Peter Bader, Krysta Schlis, Patricia A. Wood, Rajen Mody, Lan Yi, Mimi Leung, Lamis K. Eldjerou, Carl H. June, Shannon L. Maude
Summary: This study provides a comprehensive safety profile for tisagenlecleucel with a high rate of tisagenlecleucel-related adverse events. Effective management of cytokine-release syndrome is crucial. Most patients experienced B cell aplasia post-treatment and received immunoglobulin replacement, resulting in fewer infections over time.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Malihe Rezaee, Fatemeh Mohammadi, Atoosa Keshavarzmotamed, Sheida Yahyazadeh, Omid Vakili, Yaser Eshaghi Milasi, Vida Veisi, Rohollah Mousavi Dehmordi, Sepideh Asadi, Seyedeh Sara Ghorbanhosseini, Mehdi Rostami, Mina Alimohammadi, Abbas Azadi, Nushin Moussavi, Zatollah Asemi, Azadeh Aminianfar, Hamed Mirzaei, Alireza Mafi
Summary: Breast cancer is the most common cancer among women worldwide, and drug resistance is a major challenge in its treatment. Exosomal non-coding RNAs have the potential to regulate the molecular mechanisms and pathways related to breast cancer progression and drug resistance, and also serve as biomarkers for diagnosis and prognosis.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Masahiro Takada, Shigeru Imoto, Takanori Ishida, Yoshinori Ito, Hiroji Iwata, Norikazu Masuda, Hirofumi Mukai, Shigehira Saji, Takafumi Ikeda, Hironori Haga, Toshiaki Saeki, Kenjiro Aogi, Tomoharu Sugie, Takayuki Ueno, Shinji Ohno, Hiroshi Ishiguro, Chizuko Kanbayashi, Takeshi Miyamoto, Yasuhiro Hagiwara, Masakazu Toi
Summary: This study investigated the efficacy of S-1 in different recurrence risk subgroups. The results showed that adding S-1 to endocrine therapy significantly reduced the occurrence of iDFS events in group 2 and group 3. In patients with 1-3 positive lymph nodes meeting the monarchE criteria, the addition of S-1 improved iDFS.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Biology
Toshiki Kazama, Taro Takahara, Thomas C. Kwee, Noriko Nakamura, Nobue Kumaki, Naoki Niikura, Tetsu Niwa, Jun Hashimoto
Summary: This study aimed to correlate quantitative T1, T2, and proton density (PD) values with breast cancer subtypes using synthetic MRI. The results showed that T2 relaxation time was significantly higher in ER-negative cancers compared to ER-positive cancers. T1, T2, and PD values were strongly positively correlated with Ki-67. Among ER-positive cancers, Luminal A cancers had significantly lower T1, T2, and PD values compared to Luminal B cancers. Synthetic MRI-derived quantitative values show potential for subtyping invasive breast cancers.
Article
Oncology
Yi-Fan Zhou, Yi Xiao, Xi Jin, Geng-Hong Di, Yi-Zhou Jiang, Zhi-Ming Shao
Summary: This study systematically characterized the HLA-I status in triple-negative breast cancers (TNBCs) and found that HLA-I loss of heterozygosity (LOH) is an independent prognostic biomarker, especially for patients with non-immune-inflamed tumors. HLA-I LOH tumors had upregulated mutational signature 3 scores and homologous recombination deficiency scores, indicating DNA repair failure, higher mutation and neoantigen loads, and more subclones, contributing to poor immune selection pressure.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Sonia L. Villegas, Valentina Nekljudova, Nicole Pfarr, Jutta Engel, Michael Untch, Simone Schrodi, Frank Holms, Hans U. Ulmer, Peter A. Fasching, Karsten E. Weber, Christian Albig, Clemens Heinrichs, Frederik Marme, Arndt Hartmann, Claus Hanusch, Wolfgang D. Schmitt, Jens Huober, Bianca Lederer, Marion van Mackelenbergh, Hans Tesch, Christian Jackisch, Mahdi Rezai, Peter Sinn, Bruno Sinn, John Hackmann, Marion Kiechle, Andreas Schneeweiss, Wilko Weichert, Carsten Denkert, Sibylle Loibl
Summary: The study found that patients with low hormone receptor expression HER2-negative breast cancer had similar treatment response and survival rates as patients with triple-negative breast cancer, while patients with strong hormone receptor-positive breast cancer had a lower pathological complete response rate but better survival rates. Low hormone receptor expression breast cancer patients were predominantly classified into a basal-like subtype based on gene expression analysis.
EUROPEAN JOURNAL OF CANCER
(2021)